China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's (SHA:603707) drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange.

The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the filing said.

The injection is used simultaneously with abemaciclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, among other types, the filing said.

Shares closed 2% higher during Tuesday's afternoon trading.